MCID: PRR004
MIFTS: 36

Preretinal Fibrosis malady

Categories: Eye diseases

Aliases & Classifications for Preretinal Fibrosis

Aliases & Descriptions for Preretinal Fibrosis:

Name: Preretinal Fibrosis 12 14
Macular Puckering of Retina 12
Macular Retinal Puckering 12
Cellophane Maculopathy 12
Epiretinal Membrane 42

Classifications:



External Ids:

Disease Ontology 12 DOID:2006
ICD9CM 35 362.56
MeSH 42 D019773
UMLS 69 C0339543

Summaries for Preretinal Fibrosis

MalaCards based summary : Preretinal Fibrosis, also known as macular puckering of retina, is related to vitreoretinopathy, neovascular inflammatory and retinitis. An important gene associated with Preretinal Fibrosis is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and AGE-RAGE signaling pathway in diabetic complications. The drugs Dexamethasone and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include retina and eye, and related phenotypes are cardiovascular system and digestive/alimentary

Related Diseases for Preretinal Fibrosis

Diseases related to Preretinal Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
id Related Disease Score Top Affiliating Genes
1 vitreoretinopathy, neovascular inflammatory 11.0
2 retinitis 10.3
3 macular holes 10.3
4 retinal detachment 10.1
5 vitreous detachment 10.1
6 albinism, oculocutaneous, type ia 10.1 GFAP TGFB2
7 maxillary neoplasm 10.1 GFAP VEGFA
8 neurilemmoma of the pleura 10.1 GFAP VEGFA
9 cataract 10.1
10 aniseikonia 10.1
11 interstitial lung disease 10.1 GFAP VEGFA
12 submucous uterine fibroid 10.0 ANGPT2 VEGFA
13 hypersensitivity syndrome, carbamazepine-induced 10.0 ANGPT2 VEGFA
14 radiation induced angiosarcoma of the breast 10.0 ANGPT2 VEGFA
15 bipolar i disorder 10.0 ANGPT2 VEGFA
16 congenital ichthyosiform erythroderma 10.0 TGFB2 VEGFA
17 localized junctional epidermolysis bullosa, non-herlitz type 10.0 ANGPT2 VEGFA
18 granular cell leiomyosarcoma 10.0 GFAP VEGFA
19 pituitary infarct 10.0 ANGPT2 VEGFA
20 endotheliitis 10.0
21 mental retardation, autosomal recessive 27 10.0 ANGPT2 VEGFA
22 marginal zone b-cell lymphoma 10.0 GFAP VEGFA
23 vulvitis 10.0 ANGPT2 VEGFA
24 vernal conjunctivitis 10.0 ANGPT2 VEGFA
25 uveitis 10.0
26 anterograde amnesia 10.0 GFAP VEGFA
27 venous insufficiency 9.9 TGFB2 VEGFA
28 hemolytic anemia 9.9 ANGPT2 VEGFA
29 combined hamartoma of the retina and retinal pigment epithelium 9.9
30 coats disease 9.9
31 albinism, oculocutaneous, type ib 9.9 ANGPT2 VEGFA
32 adult infiltrating astrocytic neoplasm 9.9 ANGPT2 TGFB2 VEGFA
33 epidermolysis bullosa simplex, sutosomal recessive 2 9.8 ANGPT2 TGFB2 VEGFA
34 human venous malformation 9.8 ANGPT2 TGFB2 VEGFA
35 stargardt disease 9.8
36 retinitis pigmentosa 9.8
37 diabetic macular edema 9.8
38 refractive error 9.8
39 pars planitis 9.8
40 citrullinemia, type ii, neonatal-onset 9.8 ANGPT2 VEGFA
41 upper respiratory tract disease 9.7 GFAP RLBP1 TGFB2 VEGFA
42 insulin-like growth factor i 9.7
43 neurofibromatosis, type 2 9.7
44 craniopharyngioma 9.7
45 retinoschisis 9.7
46 cavernous hemangioma 9.7
47 strabismus 9.7
48 hemangioma 9.7
49 neurofibromatosis 9.7
50 retinal vein occlusion 9.7

Graphical network of the top 20 diseases related to Preretinal Fibrosis:



Diseases related to Preretinal Fibrosis

Symptoms & Phenotypes for Preretinal Fibrosis

MGI Mouse Phenotypes related to Preretinal Fibrosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 GFAP RLBP1 TGFB2 VEGFA ANGPT2
2 digestive/alimentary MP:0005381 9.46 ANGPT2 GFAP TGFB2 VEGFA
3 immune system MP:0005387 9.35 ANGPT2 GFAP LCK TGFB2 VEGFA
4 vision/eye MP:0005391 9.02 ANGPT2 GFAP RLBP1 TGFB2 VEGFA

Drugs & Therapeutics for Preretinal Fibrosis

Drugs for Preretinal Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
2
Ranibizumab Approved Phase 4 347396-82-1 459903
3
Nepafenac Approved Phase 4 78281-72-8 151075
4
Verteporfin Approved, Investigational Phase 4 129497-78-5
5 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
6 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
7
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
8 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
9 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
10 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
11 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2,Phase 1
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Angiogenesis Inhibitors Phase 4
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
16 Angiogenesis Modulating Agents Phase 4
17 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
18 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antirheumatic Agents Phase 4,Phase 3
20 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
21 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
23 Analgesics Phase 4
24 Analgesics, Non-Narcotic Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Dermatologic Agents Phase 4
27 Photosensitizing Agents Phase 4
28
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
29
Colchicine Approved Phase 3 64-86-8 6167 2833
30
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
31
Dalteparin Approved Phase 3 9041-08-1
32
Fluorouracil Approved Phase 3 51-21-8 3385
33
Lutein Approved, Nutraceutical Phase 3 127-40-2 6433159 5368396
34 triamcinolone acetonide Phase 3
35 calcium heparin Phase 3
36 Heparin, Low-Molecular-Weight Phase 3
37 Triamcinolone diacetate Phase 3
38 Triamcinolone hexacetonide Phase 3
39 Fibrinolytic Agents Phase 3
40 Anticoagulants Phase 3
41 Antimitotic Agents Phase 3
42 Calcium, Dietary Phase 3
43
Vitamin A Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 11103-57-4, 68-26-8 445354
44 Retinol palmitate Phase 1, Phase 2
45 Ophthalmic Solutions Phase 2,Phase 1
46 Pharmaceutical Solutions Phase 2,Phase 1
47 Tetrahydrozoline Phase 2
48 retinol Nutraceutical Phase 1, Phase 2
49
Bevacizumab Approved, Investigational 216974-75-3
50
Prednisolone Approved, Vet_approved 50-24-8 5755

Interventional clinical trials:

(show top 50) (show all 80)
id Name Status NCT ID Phase
1 Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery Completed NCT00818844 Phase 4
2 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4
3 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4
4 Brilliant Blue Versus Indocyanine Green Unknown status NCT01083004 Phase 3
5 Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery Unknown status NCT01820520 Phase 3
6 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3
7 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
8 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3
9 Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy Completed NCT01627977 Phase 3
10 Ozurdex for Macular Edema Post Membrane Peeling Completed NCT01273727 Phase 2, Phase 3
11 Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling Unknown status NCT00556244 Phase 1, Phase 2
12 Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal Terminated NCT00333060 Phase 2
13 PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy Completed NCT02644694 Phase 1
14 Change in Foveal Avascular Zone After Removal of Epiretinal Membrane and Internal Limiting Membrane Unknown status NCT01985490
15 Outcomes of Vitrectomy Combined With Subtenon Triamcinolone Injection for the Idiopathic Epiretinal Membrane Unknown status NCT01630876
16 Study of Retinal Sensitivity by Microperimetry During Epiretinal Membrane Surgery Unknown status NCT02084212
17 Gene Expression in Patients With Epiretinal Membranes Unknown status NCT01946451
18 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel Unknown status NCT00892619
19 Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy Unknown status NCT01969929
20 Triple Therapy for Diffuse Diabetic Macular Edema Unknown status NCT01218750
21 Prophylactic Laser Photocoagulation and Vitrectomy for Acute Retinal Necrosis Unknown status NCT02222857
22 Retinal Neurodegenerative Signs in Alzheimer's Diseases Unknown status NCT01555827
23 Microperimetry and Optical Coherence Tomography (OCT) in Idiopathic Epiretinal Membrane Completed NCT01481987
24 Study of Impact of Air vs SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping Completed NCT02030262
25 Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal Completed NCT01474655
26 Fundus Autofluorescence After Vitrectomy for Epiretinal Membrane Completed NCT02628158
27 Phacoemulsification and 25 Gauge (25G) Vitrectomy Versus Phacoemulsification Only in Idiopathic Epiretinal Membranes Completed NCT01771939
28 Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green. Completed NCT00376857
29 Topical Use of Corticosteroid to Prevent Epiretinal Membrane Following Retinal Tear Completed NCT02412059
30 Trypan Blue Versus Brillant Blue for Epiretinal Membranes Completed NCT00757380
31 Mid-term Evaluation of Metamorphopsia in Epiretinal Membrane Surgery Completed NCT03045367
32 Evaluation of the Cone Outer Segment Tips Line After Epiretinal Membrane Surgery Completed NCT01549249
33 Refractive Consequences of Epiretinal Membrane Surgery Completed NCT02413619
34 Treatment of Epiretinal Membranes With Ranibizumab Completed NCT01238393
35 Prognostic Factors in Epiretinal Membrane Surgery Completed NCT02406430
36 Prophylactic Ketorolac Post Epiretinal Membrane Surgery Completed NCT00974753
37 Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes Completed NCT01846351
38 Change of Retinally-Induced Aniseikonia in Patients With Epiretinal Membrane After Vitrectomy Completed NCT01901406
39 27-gauge Vitrectomy Wound Integrity: a Prospective, Randomized Trial Comparing Angled Versus Straight Entry Completed NCT02836210
40 UHR-OCT and HD-OCT for Preretinal Membranes: ICG Versus Membrane Blue Completed NCT00437593
41 Epiretinal Fibrosis, Effect of Early Surgery Completed NCT00902629
42 Membrane Blue Versus Infracyanine Green Completed NCT00555269
43 Vitrectomy Retinal Oxygenation Completed NCT01510691
44 Applicability of the Acai Fruit (Euterpe Oleracea) Dye for Chromovitrectomy in Humans Completed NCT02691429
45 Blue-Blocking IOLs in Combined Surgery Completed NCT00537992
46 Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies Completed NCT00408720
47 Clinicopathologic Findings for Macular Disease Completed NCT00994227
48 Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment. Completed NCT01860586
49 Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study Completed NCT01162356
50 Primary Vitrectomy for the Treatment of Retinal Detachment in Highly Myopic Completed NCT01480505

Search NIH Clinical Center for Preretinal Fibrosis

Cochrane evidence based reviews: epiretinal membrane

Genetic Tests for Preretinal Fibrosis

Anatomical Context for Preretinal Fibrosis

MalaCards organs/tissues related to Preretinal Fibrosis:

39
Retina, Eye

Publications for Preretinal Fibrosis

Articles related to Preretinal Fibrosis:

id Title Authors Year
1
Idiopathic preretinal fibrosis: a review of 237 cases. ( 1549286 )
1992
2
Idiopathic preretinal fibrosis with concurrent cystoid macular edema. ( 3429756 )
1987
3
Idiopathic preretinal fibrosis in young patient. ( 3842950 )
1985

Variations for Preretinal Fibrosis

Expression for Preretinal Fibrosis

Search GEO for disease gene expression data for Preretinal Fibrosis.

Pathways for Preretinal Fibrosis

GO Terms for Preretinal Fibrosis

Cellular components related to Preretinal Fibrosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.62 TGFB2 VEGFA

Biological processes related to Preretinal Fibrosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 9.43 ANGPT2 VEGFA
2 kidney development GO:0001822 9.4 TGFB2 VEGFA
3 hemopoiesis GO:0030097 9.37 LCK TGFB2
4 heart morphogenesis GO:0003007 9.32 TGFB2 VEGFA
5 positive regulation of cell division GO:0051781 9.26 TGFB2 VEGFA
6 activation of protein kinase activity GO:0032147 9.16 TGFB2 VEGFA
7 angiogenesis GO:0001525 9.13 ANGPT2 TGFB2 VEGFA
8 response to hypoxia GO:0001666 8.8 ANGPT2 TGFB2 VEGFA

Sources for Preretinal Fibrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....